DEA Rescheduling Hearing on June 29 Faces Pre-Emptive Legal Challenge—What It Means for Patients

Hospitals and insurers had just started adjusting their policies to account for marijuana’s move to Schedule III, expecting that FDA-approved cannabinoid medicines would soon follow with standard prescription coverage. MMJ International Holdings’ challenge reframes the entire process as an administrative trainwreck, alleging the government skipped the legally required hearing before issuing the final rule. If the D.C. Circuit agrees, the healthcare system could be thrown back into a Schedule I world where cannabis-derived drugs face near-prohibitive barriers to clinical study and insurance reimbursement—undermining treatment options for pain, epilepsy, and other conditions where early evidence shows promise.

MMJ International Holdings and its affiliates have escalated their legal confrontation with the federal government over marijuana rescheduling by filing a Statement of Issues in the D.C. Circuit Court of Appeals on June 18, 2026, seeking to vacate the April 22, 2026 Final Order that placed marijuana into Schedule III of the Controlled Substances Act. The company, which is pursuing FDA-regulated cannabinoid medicines through the traditional drug development pathway, argues the DEA and Acting Attorney General Todd Blanche exceeded their statutory authority, violated the Administrative Procedure Act (APA), ignored international treaty obligations, and deprived interested parties of statutory hearing rights. The challenge also contends the government improperly terminated an existing hearing process that had been underway since 2024 and replaced it with a new, expedited proceeding, while relying on an administrative framework that the Department of Justice has acknowledged contains constitutional defects.

“

The legal filing comes just days before a DEA hearing on the rescheduling order set for June 29, 2026, but MMJ’s CEO Duane Boise insists the more consequential event is the appellate court review.

The legal filing comes just days before a DEA hearing on the rescheduling order set for June 29, 2026, but MMJ’s CEO Duane Boise insists the more consequential event is the appellate court review. The company’s positioning as both a drug developer and a challenger places it in a unique dual role: on one hand, rescheduling to Schedule III would theoretically ease some research restrictions and tax burdens for pharmaceutical cannabinoid development; on the other, MMJ argues the process was so procedurally flawed that the entire order should be voided, potentially returning marijuana to Schedule I and resetting the regulatory landscape.

For the biotech and pharmaceutical industries, this case highlights the precarious interplay between agency rulemaking and statutory mandates when it comes to controlled substances. Companies investing heavily in cannabinoid-derived therapeutics have been navigating a shifting regulatory environment since HHS recommended rescheduling in 2023. The DEA’s eventual Final Order was celebrated by many industry players as a breakthrough, but MMJ’s challenge underscores deep fissures. The assertion that the government sidestepped the CSA’s required hearing process—by first terminating an existing multi-year hearing and then issuing a final rule before a new hearing could conclude—raises existential questions about the validity of the entire Schedule III determination. If the D.C. Circuit grants vacatur, the entire rescheduling action could unravel, throwing into disarray the business plans of dozens of companies that had banked on the lower regulatory bar.